Investors Eye Big Gains With Potential Cure for Blindness
By: Rex Moore
What do most investors dream of?
Getting into a world-changing technology early — before the big crowds do — and then hanging on while their stock takes off faster than a rocket. That’s where the huge gains are, and investing in even one of these moonshots can set you up financially for life.
Like the 53,700% gains for anyone who followed a certain Virginia investor's recommendation to buy Amazon.com in 1997… more about that in just a second.
But this is where this potential cure for blindness comes in. It’s obviously a big, BIG deal… and yet most people aren't even aware of it. Are you and your friends even talking about it?
Yet this technological breakthrough is so mind-blowing because it is able to supercharge medical progress to the extent that research is moving along magnitudes faster, and much more cheaply, than conventional methods.
How much faster? NPR reports that what previously took years can now be achieved in just weeks! According to the report, “It's literally the most revolutionary aspect of this development, that scientists in laboratories are moving at tremendous speed.”
How much more cheaply? MIT reports that this technology is up to 150 times cheaper than previous techniques. AND… work that used to take nine people now only takes one.
And because of this amazing efficiency… a cure for blindness is just a small part of what scientists are hoping to use this tech for.
The company that currently controls several crucial patents for this remarkable technology is building out a pipeline that also addresses other hereditary conditions of the liver, blood, lungs, and muscles.
Meaning… possible cures are on the horizon for certain forms of leukemia and diabetes, and even heart disease reversal!
It's so promising that Bloomberg calls it “The discovery of the century.”
Motley Fool Biotech Expert Karl Thiel says “I've followed the biotechnology industry for a long time, and I don't think I've ever seen anything as exciting.”
You can see why I’m so excited about this as an investor.
How to invest
When you consider that Deloitte predicts the global healthcare market to grow to $8.7 trillion by 2020…well, it’s not hard to see why some of the sharpest minds on Wall Street are starting to see dollar signs.
One of the world’s greatest growth stock investors has issued a buy recommendation on the tiny company at the forefront of this incredible breakthrough.
His name is David Gardner, co-founder of The Motley Fool…and he first became famous buying Amazon for $3.19 a share in 1997… which has produced that incredible return I mentioned at the start of this article.
Investors smart enough to follow David’s recommendation that day… have turned every $5,000 invested into well over $4.1 million!
And David has over a dozen other recommendations that have exceeded the 1,000% threshold.
I’m talking about picks like:
- Netflix, up 17,784%
- Walt Disney, up 3,386%
- Nvidia, up 3,580%
And that’s why I think you’ll want to find out all about this remarkable breakthrough today.
Because as you can see…getting in early on a tech tidal wave can be incredibly lucrative.
And the good news is you can read all about this incredible opportunity today.
Because I’ve packed all the details into a brand-new report.
And even better…this report is free to you today!
But please do not delay…because history has taught us that the big money goes to early investors…and there’s no way that this tech will stay quiet for long.
An $8.7 Trillion Opportunity Hiding in Plain Sight
An incredible breakthrough is poised to upend the $8.7 trillion worldwide healthcare market. And one remarkable company is at the white-hot center of this biotech boom.
Simply enter your email below to get the full story.
Returns data as of May 22, 2018. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Rex Moore owns shares of Nvidia. The Motley Fool owns shares of and recommends Amazon, Netflix, Nvidia, and Walt Disney. The Motley Fool has a disclosure policy.